Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Moxifloxacin
Drug ID BADD_D01501
Description Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.
Indications and Usage For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).
Marketing Status approved; investigational
ATC Code J01MA14; S01AE07
DrugBank ID DB00218
KEGG ID D08237
MeSH ID D000077266
PubChem ID 152946
TTD Drug ID D0ZV0Z
NDC Product Code 65977-0038; 51407-321; 63629-8357; 0378-5430; 65862-840; 72189-321; 16714-643; 50090-6357; 55111-112; 70518-3713; 80425-0239; 50090-5833; 53002-2723; 68180-421; 61919-553; 72789-233; 60505-0582; 68180-422; 72189-334; 17478-519; 31722-845; 0904-6406; 12527-0517; 50090-3147
UNII U188XYD42P
Synonyms Moxifloxacin | 1-Cyclopropyl--7-(2,8-diazabicyclo(4.3.0)non-8-yl)-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid | Octegra | Proflox | Moxifloxacin Hydrochloride | Avelox | Avalox | Izilox | Actira | BAY 12-8039 | BAY 12 8039 | BAY-12-8039 | BAY 128039 | BAY-128039 | BAY128039
Chemical Information
Molecular Formula C21H24FN3O4
CAS Registry Number 151096-09-2
SMILES COC1=C2C(=CC(=C1N3CC4CCCNC4C3)F)C(=O)C(=CN2C5CC5)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Insomnia19.02.01.002; 17.15.03.0020.000296%
Intentional self-injury19.12.01.002; 12.01.08.036--Not Available
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.004--Not Available
Joint swelling15.01.02.004--Not Available
Lacrimation increased06.08.02.0040.000404%
Laryngeal oedema10.01.05.003; 23.04.01.005; 22.04.02.001--
Lethargy19.04.04.004; 17.02.04.003; 08.01.01.008--
Leukocytosis01.02.01.002--
Leukopenia01.02.02.001--Not Available
Lip swelling23.04.01.007; 10.01.05.005; 07.05.04.005--Not Available
Lipase increased13.05.01.003--
Liver disorder09.01.08.001--Not Available
Liver function test abnormal13.03.04.030--Not Available
Loss of consciousness17.02.04.004--Not Available
Malaise08.01.01.003--
Mean cell haemoglobin normal13.01.05.024--Not Available
Mental impairment19.21.02.003; 17.03.03.002--Not Available
Micturition urgency20.02.02.006--
Migraine24.03.05.003; 17.14.02.001--Not Available
Mood altered19.04.02.007--Not Available
Mouth haemorrhage24.07.02.014; 07.05.02.001--
Movement disorder17.01.02.010--Not Available
Muscle atrophy17.05.03.004; 15.05.03.003--Not Available
Muscle contractions involuntary17.05.03.001; 15.05.03.008--Not Available
Muscle spasms15.05.03.004--
Muscle twitching15.05.03.005--Not Available
Muscular weakness17.05.03.005; 15.05.06.001--
Musculoskeletal pain15.03.04.007--
Myalgia15.05.02.001--
Myasthenia gravis17.05.04.001; 15.05.08.001; 10.04.05.001--
The 6th Page    First    Pre   6 7 8 9 10    Next   Last    Total 11 Pages